Fzata's FZ002: A New Hope in Treating C. difficile Infections Fzata, Inc. has partnered with the NIH to launch a Phase 1 trial for FZ002, a novel oral therapy targeting C. difficile, promising safer treatment options.

Fzata's FZ002: A New Hope in Treating C. difficile Infections #United_States #Halethorpe #C._difficile #Fzata #FZ002